Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes. By inhibiting SGLT2 expressed in the kidney, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.
Dapagliflozin was approved in the EU in 2012, in the US and in Switzerland in 2014.
Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors
ATC Codes: A10BK01; A10BD15, A10BD21, A10BD25 (combinations)